Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes
暂无分享,去创建一个
Li Ding | Cyriac Kandoth | Timothy A. Graubert | Matthew J. Walter | John F. DiPersio | Timothy J. Ley | Elaine R Mardis | Joelle M. Kalicki-Veizer | Jack Baty | Michael McLellan | R. Wilson | R. Fulton | E. Mardis | L. Ding | M. McLellan | Heather K. Schmidt | T. Ley | C. Kandoth | M. Walter | D. Shen | M. O'Laughlin | J. Baty | P. Westervelt | T. Graubert | J. Dipersio | J. Shao | Richard K. Wilson | Robert Fulton | M. Grillot | Peter Westervelt | Heather Schmidt | Dong Shen | Jin Shao | Joelle Kalicki-Veizer | Marcus Grillot | Michelle O’Laughlin | R. Wilson | Marcus Grillot
[1] S. Henikoff,et al. Predicting deleterious amino acid substitutions. , 2001, Genome research.
[2] N. Tommerup,et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene , 1999, Nature.
[3] Kelly M. McGarvey,et al. The cancer epigenome--components and functional correlates. , 2006, Genes & development.
[4] D. Haber,et al. DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.
[5] Hideo Ema,et al. De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells , 2007, The Journal of experimental medicine.
[6] E. Passegué,et al. PML-RAR{alpha} and Dnmt3a1 cooperate in vivo to promote acute promyelocytic leukemia. , 2010, Cancer research.
[7] M. Esteller. Epigenetics in cancer. , 2008, The New England journal of medicine.
[8] John M Bennett,et al. Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.
[9] C. Nislow,et al. Mammalian homologues of the Polycomb‐group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S.cerevisiae telomeres , 1997, The EMBO journal.
[10] N. Casadevall,et al. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? , 2005, Leukemia.
[11] Lucy Skrabanek,et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. , 2009, Blood.
[12] R. Kuiper,et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.
[13] Peter A. Jones,et al. Epigenetics in cancer. , 2010, Carcinogenesis.
[14] R. Levine,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.
[15] A. Jeltsch,et al. Mutational analysis of the catalytic domain of the murine Dnmt3a DNA-(cytosine C5)-methyltransferase. , 2006, Journal of molecular biology.
[16] A. Hagemeijer,et al. Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.
[17] D. Birnbaum,et al. Myelodysplastic syndromes: lost between two states? , 2010, Leukemia.
[18] J. Licht,et al. DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.
[19] P. Bork,et al. Human non-synonymous SNPs: server and survey. , 2002, Nucleic acids research.
[20] L. Aravind,et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 , 2010, Nature.
[21] R. Weinberg,et al. Suppression of intestinal neoplasia by DNA hypomethylation , 1995, Cell.
[22] T. Naoe,et al. Array-based genomic resequencing of human leukemia , 2010, Oncogene.
[23] Fabien Campagne,et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.
[24] H. Drexler,et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.
[25] M. Walter,et al. Integrated Genomic Analysis Implicates Haploinsufficiency of Multiple Chromosome 5q31.2 Genes in De Novo Myelodysplastic Syndromes Pathogenesis , 2009, PloS one.
[26] E. Li,et al. Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting , 2004, Nature.
[27] C. O'keefe,et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. , 2009, Blood.
[28] D. Gilliland,et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML , 2009, Leukemia.
[29] M. Kyba,et al. The Additional sex combs gene of Drosophila encodes a chromatin protein that binds to shared and unique Polycomb group sites on polytene chromosomes. , 1998, Development.
[30] P. Ritch,et al. Evaluation of continuous infusion low‐dose 5‐azacytidine in the treatment of myelodysplastic syndromes , 1991, American journal of hematology.
[31] S. Henikoff,et al. Accounting for human polymorphisms predicted to affect protein function. , 2002, Genome research.
[32] D. Higgs,et al. Articles on similar topics can be found in the following Blood collections , 2002 .
[33] J. Dipersio,et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Holland,et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. Riesner,et al. Induction of Tumors in Mice by Genomic Hypomethylation , 2003 .
[36] Min Gyu Lee,et al. Demethylation of H3K27 Regulates Polycomb Recruitment and H2A Ubiquitination , 2007, Science.
[37] Jungwon Huh,et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. , 2009, Blood.
[38] G. Mufti,et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] T. Bestor,et al. Eukaryotic cytosine methyltransferases. , 2005, Annual review of biochemistry.